A cell-level model of pharmacodynamics-mediated drug disposition.

about

A cell-level model of pharmacodynamics-mediated drug disposition.

Item

http://www.wikidata.org/entity/Q39406092

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A cell-level model of pharmacodynamics-mediated drug disposition.

@en

A cell-level model of pharmacodynamics-mediated drug disposition.

@nl

type

Item

label

A cell-level model of pharmacodynamics-mediated drug disposition.

@en

A cell-level model of pharmacodynamics-mediated drug disposition.

@nl

prefLabel

A cell-level model of pharmacodynamics-mediated drug disposition.

@en

A cell-level model of pharmacodynamics-mediated drug disposition.

@nl

P1476

A cell-level model of pharmacodynamics-mediated drug disposition.

@en

P2093

John M Harrold

http://www.w3.org/2001/XMLSchema#string

Juan Jose Perez-Ruixo

http://www.w3.org/2001/XMLSchema#string

Liviawati S Wu

http://www.w3.org/2001/XMLSchema#string

Wojciech Krzyzanski

http://www.w3.org/2001/XMLSchema#string

P2860

Cell surface receptors for signal transduction and ligand transport: a design principles study.

Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects.

Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Comparison of four basic models of indirect pharmacodynamic responses

Mechanistic models for myelosuppression.

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL.

Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics.

Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

P2888

s10928-016-9491-z

P304

513-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10928-016-9491-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27612462

http://www.w3.org/2001/XMLSchema#string